Corcept's research and clinical development are focused on antagonizing or blocking the GR-II receptor, also known as the cortisol receptor. Cortisol, sometimes referred to as the “stress hormone” plays an important role in healthy individuals. However, in excess or at irregular levels it is implicated in a broad range of metabolic and psychiatric diseases.

Corcept has numerous GR-II antagonists in its portfolio and a discovery platform that continues to identify additional compounds for development. Our work extends from discovery and advanced preclinical development through to Phase 3 clinical trials to evaluate the broad potential of this platform and its specific application to a number of metabolic and psychiatric disorders.